STARCH Application Data

Similar documents
Lactose Free, Direct Compression Formulation Used to Produce Loratadine (10 mg) Tablets

Development of USP Delayed Release Aspirin Tablets using Opadry Enteric, Acrylic-Based Coating System

STARCH Proven and Trusted Excipient for Performance and Versatility EXCIPIENTS. Effective and economical disintegrant

The Relevance of USP Methodology in the Development of a Verapamil Hydrochloride (240 mg) Extended Release Formulation

Narrowing the gap between clinical capsule formulations and commercial film-coated tablets

Assessment of Low Dose Content Uniformity of Indomethacin in Excipient Blends Using FT-Raman Mapping Spectroscopy

The Effect of Film Coating and Storage Conditions on the Performance of Metformin HCl 500 mg Extended Release Hypromellose Matrices

Direct Compression Formulation Using Starch 1500 with Ranitidine HCl (150 mg) Tablets, Film Coated with Opadry II (85F Series)

Table 1. Coating Parameters

Designed and manufactured specifically for pharmaceutical capsule filling

LubriTose Mannitol Michael Crowley, Director of R&D, Excipients

Formulation and Evaluation

Opadry Enteric. Application Data. Drug Release from Acrylic-Based Opadry Enteric (94 Series) Coated Tablets INTRODUCTION MATERIALS AND METHODS

Comparative Evaluation of Enteric Film Coatings Applied in Organic Solvents

FORMULATION AND EVALUATION OF PIROXICAM AND CELECOXIB TABLETS EMPLOYING PROSOLVE BY DIRECT COMPRESSION METHOD

Int. Res J Pharm. App Sci., 2014; 4(1):47-51 ISSN:

TECHNICAL INFORMATION RxCIPIENTS FM A versatile excipient for orally disintegrating tablet (ODT) formulations

Direct Compression. With the right ingredients it s a simple, cost-effective manufacturing process

Technical brochure StarLac

Content Uniformity of Direct Compression tablets

Excipient Quality & Trouble Shooting. By Seema Trivedi GM, Technical

(12) Patent Application Publication (10) Pub. No.: US 2003/ A1

Available online Research Article

VIVAPHARM PVP/VA. Copovidone, Ph.Eur. USP/NF, JPE, E. The Ultimate Tablet Binder for All Processing Technologies

The unlocked synergy of DFE Pharma MCC

Protection and Processing of a Highly Hygroscopic Herbal Extract by Drug Layering and Film Coating

Re-compaction properties of lactose and microcrystalline cellulose

Application of Starches, Modified Starches and Starch Derivatives in Pharmaceutical Products

OCE TABLETING DIRECT COMPRESSION CO-PROCESSED LACTOSE. Technical brochure MicroceLac 100

Granulation Aggregation

Easy, fast and reliable!

Pharma & Food Solutions. POLYOX TM Water Soluble Resins Combining Flexibility with Consistency

Ingredients adapted to a fit for use model. APIs allowed the fit for use strategy to work. There has been a shift to designed for purpose

EP B1 (19) (11) EP B1 (12) EUROPEAN PATENT SPECIFICATION

Formulation and In-vitro evaluation of immediate release Olanzapine tablets

Evaluation of different binders for roller compaction R. Wang, W. Liu, T. Durig

CHAPTER 5: FORMULATION OF SOLID DOSAGE FORM (TABLET & CAPSULES) INTRODUCTION

Formulation Development of Aceclofenac Tablets Employing Starch Phosphate -A New Modified Starch

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY

FORMULATION AND DEVELOPMENT OF ER METOPROLAOL SUCCINATE TABLETS

Wettable Magnesium Stearate. What Are Customers Looking for in Selecting Pharmaceutical Lubricants?

Formulation and In-vitro Evaluation of Chewable Tablets of Montelukast Sodium

The binding performance of DFE Pharma Starch

Formulation and Evaluation of Rosuvastatin Immediate Release Tablets 10 Mg

PHARMACEUTICAL TECHNOLOGY REPORT. Introduction. Experimental Methods

Co-Processed Excipients: Regulatory Challenges. Carl Mroz Colorcon Limited June 2009

Adopting Technologies to Enhance Quality in Manufacturing

FLORITER. New Technology for Innovative Formulation Design.

FORMULATION DEVELOPMENT AND EVALUATION OF FENOFIBRATE CAPSULES

PREPARATION AND EVALUATION OF STARCH - PEG 1500 CO-PROCESSED EXCIPIENT AS A NEW DIRECTLY COMPRESSIBLE VEHICLE IN TABLET FORMULATIONS

A Comparative Evaluation of Cross Linked Starch Urea-A New Polymer and Other Known Polymers for Controlled Release of Diclofenac

IJRPC 2012, 2(3) Chowdary et al ISSN: INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY

Effect of superdisintegrants and their mode of incorporation on disintegration time and release profile of carbamazepine from immediate release tablet

Primellose is an excellent choice as superdisintegrant in ODT applications

SENTRY TM POLYOX Water Soluble Resins

Research Paper The Effect of Different Superdisintegrants and their Concentrations on the Dissolution of Topiramate Immediate Release Tablets

Effect of Compaction Forces on Powder Bed Permeability of Magnesium Silicate "Common Excipient Mixture"

STUDIES ON EFFECT OF BINDERS ON ETORICOXIB TABLET FORMULATIONS

Easy, fast and reliable!

Formulation And Evaluation Of Flurbiprofen Matrix Tablets For Colon Targeting

Figure 1: SEM Mannogem EZ (1000x)

Formulation and evaluation of oro-dispersible tablets of lafutidine

DESIGN AND EVALUATION OF CONTROLLED RELEASE MATRIX TABLETS OF FLURBIPROFEN

DISSOLUTION ENHANCEMENT OF CARVEDILOL BY USING SURFACTANT AS A COATING MATERIAL

Contract Manufacturing Fluid Bed Technology. Drying. Spray granulation. Coating. Agglomeration. Instantization.

525 International Journal of Current Trends in Pharmaceutical Research

Evaluation of Moisture Sorption Methods for Aqueous Moisture Barrier Coatings D. Tewari, R. Lewis, B. Kinsey and T. Dürig*

Volume: 2: Issue-3: July-Sept ISSN FORMULATION AND EVALUATION OF SUSTAINED RELEASE MATRIX TABLETS OF NICORANDIL

Technical brochure CombiLac

Asian Journal of Pharmacy and Life Science ISSN Vol. 2 (2), July-Sept,2012

Short Communication. Formulation of Furosemide Dispersible Tablets for Use in Paediatrics V. V. ABWOVA, P. N. MBEO, L. J. TIROP AND K. A. M.

Table 1 Hydrophilicity of MC and HPMC Grades. Polymer Cloud Point ( C) Hydrophilicity MC HPMC Type 2910 HPMC Type

CONTENTS PAGE. Please note: Preface Matrix system Selection of METOLOSE grades Specifications

REVISION OF MONOGRAPH ON TABLETS. Tablets

PHARMACEUTICAL AID PREPARED BY B.KIRUTHIGA LECTURER DEPT OF PHARMACEUTICAL CHEMISTRY

Wherever life takes you BASF excipients for orally disintegrating tablets make medication easy

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

TABLET DESIGN AND FORMULATION

J.Ayyappan et al, /J. Pharm. Sci. & Res. Vol.2 (7), 2010,

SUSTAINED RELEASE TABLETS USING A PVA DC FORMULATION RESISTANT TO ALCOHOL INDUCED DOSE DUMPING

Journal of Chemical and Pharmaceutical Research

Optimization of valsartan tablet formulation by 2 3 factorial design

Typical Opadry II coating conditions with a product bed temperature of around o C were found to be suitable

Kollidon CL Kollidon CL-F Kollidon CL-SF Kollidon CL-M. Super-disintegrants and dissolution enhancers.

Pharma Ingredients & Services. Ibuprofen. Technical Information. = Registered trademark of BASF group USP, Ph. Eur., JP

FORMULATION AND EVALUATION OF VALSARTAN TABLETS EMPLOYING CYCLODEXTRIN-POLOXAMER 407-PVP K30 INCLUSION COMPLEXES

STABILITY STUDIES OF FORMULATED CONTROLLED RELEASE ACECLOFENAC TABLETS

Evaluation of native and modified starch dispersions in mucilage obtained from sweet potato in ascorbic acid chewable tablet formulations

346 Full Text Available On

Dissolution control of direct compression tablets in different test media using novel pregelatinized starch, Swelstar TM MX-1

Preformulation Study. CHAPTER 3 Preformulation Study. 3.0 Introduction

Innovations in Pharmaceuticals and Pharmacotherapy.

Continuous Granulation Using a Twin-Screw Extruder. Lin Zhu, Ph.D. Manufacture Science and Technology AbbVie June, 2016

DVA Symposium Mexico City Anisul Quadir Ph.D, MBA SE Tylose USA, Inc. (A Shin-Etsu Chemical Group Co.) Totowa, NJ

Excipient Considerations for Continuous Manufacturing Implementation

Formulation Development of Nimesulide Tablets by Wet Granulation and Direct Compression Methods Employing Starch Citrate

Kolliwax HCO. Technical Information. Hydrogenated castor oil powder for pharmaceutical use. = Registered trademark in many countries.

LAB.2. Tablet Production Methods

INTERNATIONAL RESEARCH JOURNAL OF PHARMACY ISSN Research Article

Transcription:

STARCH 1500 Application Data Partially Pregelatinized Maize Starch Starch 1500, Partially Pregelatinized Maize Starch, Used as a Binder Disintegrant in High Shear Wet Granulation Comparison to Povidone and Croscarmellose Sodium INTRODUCTION Historically, the majority of formulations in the development of new drug products contained native corn (maize) starch, which was used as both a binder and disintegrant. As a binder, the starch was converted to a paste before adding it to the wet granulation. As a disintegrant, it was added dry to the powder blend. Both methods were used frequently, because the starch lost much of its disintegration properties when it gelatinized in the preparation of the starch paste. As a dry addition to a granulation, the native corn starch did not flow well and was not very compressible. Polymers Today, polymers such as Povidone (PVP) are preferred as binders for wet granulated products. When hydrated, these binders produce viscous, tacky solutions. The tackiness holds the individual granules together. However, polymer binders can also lead to processing difficulties such as rapid over-granulation. Over time, they occasionally lead to tablet hardening and a decrease in dissolution performance. Because a balance must be maintained between the binding and the disintegration properties of a formulation, when polymer binders are chosen, the addition of strong disintegrants, such as super disintegrants, are typically required. These materials surpass native corn starch in their ability to wick moisture and swell. However, super disintegrants are considerably more expensive and can have a negative effect on product stability as well as the film coating appearance of the finished product. Current Processing Methods High shear wet granulation is a preferred manufacturing method in many companies today. The high shear method allows for rapid production of compressible granulations. The resultant granulation characteristics depend on a combination of formulation properties and processing parameters. High- shear wet granulated products are typically dense due to the shear forces created during the high speed mixing in combination with the agitator blades. Polymers used in high shear wet granulation processing again require the addition of a disintegrant. Using hot starch pastes as an alternative is not recommended because the introduction of heat can cause process variations. Cold pastes can be processed, but time is lost while waiting for the pastes to cool thus negating the benefits of the high shear functionality. STARCH 1500-1 -

Pregelatinized Starch Alternatives An alternative to native corn starch or polymers for wet granulations is pregelatinized starch. This is a starch that has been previously gelatinized and dried to powder form. Functionally, pregelatinized starches are split into two groups, fully pregelatinized and partially pregelatinized. Fully pregelatinized starches are being used as binders in wet granulated formulations. But due to the gelatinization, much of the disintegration properties are lost. Partially pregelatinized starches on the other hand, have a mixture of properties of both native and fully gelatinized starches. This makes them useful as both a binder and a disintegrant in wet granulated formulations. High shear wet granulation is also well suited for the use of partially pregelatinized starches. Partially pregelatinized starches can be hydrated with cold water to produce viscous slurries or, alternately, can be added directly to the granulator bowl and water can be utilized to granulate. STUDY OBJECTIVES This study compares the high shear granulation and tablet properties of two formulations. One is based on a polymer granulation binder, PVP, in combination with a super disintegrant, croscarmellose sodium (CCS). This formulation was developed external to Colorcon. The other formulation utilized partially pregelatinized maize starch, Starch 1500, as both the binder and the disintegrant. MATERIALS AND METHODS Table 1 lists the formulations evaluated for this study. The grades and sources of the materials follow: guaifenesin USP (Delta Synthetic Co), microcrystalline cellulose NF intragranular (EMCOCEL 50M; JRS Pharma), microcrystalline cellulose NF extra-granular (EMCOCEL 90M; JRS Pharma), croscarmellose sodium NF (Ac-Di-Sol; FMC BioPolymer), povidone USP (Kollidon 30; BASF), magnesium stearate NF (Mallinckrodt), pregelatinized starch NF (Starch 1500; Colorcon), colloidal silicon dioxide NF (CAB-O-SIL M-5P; Cabot), stearic acid NF (Oleotec). The granulation process was carried out in a TK Fielder PMAT-10 (Niro Inc). The batch size was maintained at 2.0 kg for each trial. Materials were pre-blended for two minutes prior to granulating with an impeller speed of 300 RPM and chopper speed setting of II. Moisture content of the pre- blended ingredients was measured by loss on drying (LOD) with an Ohaus moisture balance at a temperature of 75 C. Granulation was performed by adding povidone solution or water to the granulator while mixing with an impeller speed of 300 RPM and a chopper speed setting of I. Each granulation batch used the same quantity of water to granulate, theoretically, 21% or 525 ml. The granulating solution was added through a binary spray gun at a rate of 150 g/min and an atomization pressure of 5 psi. After the addition of the liquid, the batch was worked for three minutes with an impeller speed of 300 RPM and a chopper speed setting of II. Drying was done using a Glatt GPCG-3 fluid bed processor with an inlet of 50 C. Each batch was dried to a moisture content close to the pre-blend LOD measured earlier. STARCH 1500-2 -

Final sizing of the granulations was performed by hand, using an 18 mesh screen. Lubricants were passed through a 60 mesh screen prior to blending. In addition, the colloidal silicon dioxide was passed through a 30 mesh screen along with the MCC. Blending was performed with a Patterson Kelley twin shell, four quart blender. All ingredients except the lubricant were blended for 10 minutes. The lubricant was added and blended for an additional 5 minutes. Particle size analysis was performed with an ATM Sonic Sifter under the following conditions: sample size 10 g ± 0.5 g, test time 5 minutes, amplitude 4, sift-pulse setting. The geometric mean particle sizes and standard deviations were determined by plotting the weight percent greater than a given diameter (on a probability scale) versus the log of the diameter and performing a linear regression. Bulk and tapped density was performed in accordance with USP 28 method 1. Tablets were compressed on an instrumented (SMI), Piccola (Riva), 10 station, rotary compression machine fitted with 11mm round, standard concave tooling. For each formulation, a compression profile was generated covering 6 to 24 kn at a turret speed of 30 RPM. Tablet properties were evaluated after compression with an Erweka Multicheck using a sample size of 10 tablets. Friability was evaluated at 100 drops using an Erweka Friabulator. Disintegration times were measured according to USP 28 with an Erweka DT bath using deionized water; the median disintegration time was reported. Dissolution was performed according to USP 28 in DI water with an automated VanKel dissolution apparatus and the samples were analyzed by UV at a wavelength of 274 nm. RESULTS AND DISCUSSION In addition to film coating support, Colorcon provides formulation services to customers using Colorcon products. The work contained within this paper was driven by providing a comparative formulation for a customer. The polymer/super disintegrant formulation was derived from a similar customer formulation but with a different drug substance. Guaifenesin, a water soluble, high dose drug, was chosen as a model drug for these experiments. Guaifenesin is difficult to granulate and melts at a low temperature. Formula 1 is listed in Table 1 and utilizes common granulation excipients. The quantity of each ingredient was chosen to be within the recommended use levels. The granulation contains microcrystalline cellulose (MCC) at approximately 20% both internally and externally to the granulation. MCC can lose some compactability when used in wet granulations, therefore, it is desirable to incorporate a portion of it externally to ensure good tablet hardness. The 90 micron grade of MCC was used externally. The dissolution performance of a granu- lated formulation can be improved using super disintegrants both internally and externally to the granulation. CCS is used at 4% of the formulation and was split equally between the phases. Magnesium stearate was used as the lubricant for this formulation at a level of 1%. This level may not always be warranted in most formulations but many times it is selected without optimization in order to avoid any potential ejection force issues during compression. Since these ingredient levels were not originally determined by Colorcon, they were not altered for this study. STARCH 1500-3 -

Table 1. Formula 1 Formula 2 Ingredient Percent mg/tablet Percent mg/tablet Granulation Guaifenesin USP 69.77% 300.00 69.77% 300.00 Microcrystalline Cellulose NF 10.00% 43.00 - - Croscarmellose Sodium NF 2.00% 8.60 - - Povidone USP 5.00% 21.50 - - Pregelatinized Starch NF - - 16.00% 68.80 Dry Additions Microcrystalline Cellulose NF 10.23% 44.00 9.48% 40.77 Croscarmellose Sodium NF 2.00% 8.60 - - Magnesium Stearate NF 1.00% 4.30 - - Pregelatinized Starch NF - - 4.00% 17.20 Stearic Acid NF - - 0.50% 2.15 Colloidal Silicon Dioxide NF - - 0.25% 1.08 Total 100.00% 430.00 100.00% 430.00 Formula 2 was created using Starch 1500 as both the granulation binder and the disintegrant. Because Starch 1500 is a partially pregelatinized starch it maintains beneficial properties of both native starch and fully pregelatinized starch. Table 1 lists the ingredients for this formulation. All of the PVP and the CCS were replaced with Starch 1500. In addition, the internal MCC was also replaced with Starch 1500. The external CCS was replaced with Starch 1500, but at twice the level. Starch 1500 is an effective disintegrant but it is not a super disintegrant and typically needs to be used at higher levels to gain similar disintegration performance. The level in the external phase was 4%. The total Starch 1500 content in the formulation was 20%. Magnesium stearate was replaced with stearic acid and colloidal silicon dioxide. Magnesium stearate can be detrimental to particle bonding in plastically deforming materials such as pregelatinized starch and MCC. Magnesium stearate is a more effective lubricant than stearic acid, therefore, when used at the same level, magnesium stearate should produce lower ejection forces than stearic acid. Since Formula 2 contained 20% Starch 1500, a reduced level of stearic acid was chosen because Starch 1500 also has self lubricating properties. The addition of colloidal silicon dioxide to the formulation is important when using stearic acid since it does not have anti-adherent properties. The inclusion of colloidal silicon dioxide, at half the level of the stearic acid, will keep product from adhering to the punch faces. The level of the external MCC was then adjusted in order to maintain the tablet weight of 430 mg. Both granulations produced during this study were of acceptable quality. Tables 2 and 3 show the granulation properties. Formula 1 produced a slightly denser granulation and also produced a larger mean particle size than Formula 2. This can be attributed to the difference between adding the binder in solution versus dry. When all of the binder is solubilized, there is greater binding strength. STARCH 1500-4 -

Table 2. Granulation Densities Average Bulk Density Average Tapped Density Average Carr s Index Product Unit g/cc g/cc % Formula 1 0.590 0.675 12.6 Formula 2 0.570 0.680 16.1 Product Table 3. Granulation Particle Size Granulation Geometric Mean Geometric Standard Deviation Final Blend Geometric Mean Geometric Standard Deviation Unit µm NA µm NA Formula 1 194 2.28 169 2.64 Formula 2 178 2.37 144 2.47 Figure 1 shows the difference in geometric mean particle sizes of the raw granulations and the final blends. Since external ingredients are being added to the granulation, a shift in the mean particle size is seen. Figure 1. Geometric Mean Particle Size Table 4 lists the moisture content of the granulations at different points within the manufacturing process. Since Starch 1500 has a moisture content of approximately 9%, the pre- blend LOD for Formula 2 is slightly higher than Formula 1. Product Table 4. Granulation Moisture Levels Pre-Blend LOD Wet LOD Gran. Final LOD Final Blend LOD Unit % % % % Formula 1 0.4 14.7* 1.0 1.3 Formula 2 1.3 19.8* 1.6 2.0 *Some melting on moisture balance. STARCH 1500-5 -

The compressibility of many pharmaceutical ingredients is sensitive to moisture content. The pre-blend LOD represents the natural moisture condition of the ingredients in the granulation prior to granulating. During development, a formulator would evaluate different drying endpoints in order to produce granulation moisture contents above and below the normal condition. These would then be evaluated to determine the impact on tableting performance. Each granulation batch used the same quantity of water to granulate, theoretically 21%. The data values for the wet LOD s are not valid due to melting and evaporation of the drug on the moisture balance. In order to add the granulating fluid to the product, a spray gun was utilized with both formulations. Previous trials without utilizing a spray gun led to the creation of many small agglomerates in the granulator. Due to the aggressiveness of the PVP binder, if the solution was not atomized or dispersed finely, agglomerates formed as the solution contacted the dry powders. Depending on the number and size of these agglomerates, the batch may require wet milling prior to drying. When trials without a spray gun were run with Starch 1500 as the binder, no agglomerates were produced giving a more uniform granulation. This could save considerable manufacturing time by eliminating the need for wet milling. Figure 2 displays the tablet hardness of the two formulations. Both produced tablets of similar hardness in the lower range of compression force. In the upper range, Formula 2 produced tablets of higher hardness than Formula 1. This formula, containing Starch 1500 and MCC, utilized a better choice of lubricant. Stearic acid allows for better bonding of these plastically deforming materials. Figure 2. Compression Profile Figure 3 shows the friability profiles of the products. Again, both formulations produced similarly low friabilities. For nearly every point, Formula 2 produced lower friabilities than Formula 1. Tablets must be of sufficient hardness and have low friability in order to withstand further unit operations such as film coating, printing, and packaging. STARCH 1500-6 -

Figure 4 plots the ejection forces for each formulation. Formulation 2, which used stearic acid, a less effective lubricant than magnesium stearate, produced slightly higher ejection forces than Formula 1. Stearic acid is commonly used at twice the level of magnesium stearate. Both formulations, however, provide effective lubrication with values less than 400 N being preferable on this tablet press. Figure 3. Friability Profile Figure 4. Ejection Profile STARCH 1500-7 -

Figure 5 details the disintegration performance of the two formulations. At all compression forces tested, Formula 2 produced disintegration times that were lower than those for Formula 1 containing super disintegrant. Figure 5. Median Disintegration Profile Figure 6 represents the dissolution data for both formulations. While both meet the USP specifications, Formula 2 produced a more rapid release of the drug. This is due to the inclusion of Starch 1500 in the formulation. In contrast to Formula 1, Starch 1500 performs not only as a binder but also is an effective disintegrant allowing the tablet to break down at a faster rate. Tablets used to produce dissolution data were compressed at the same force, 12 kn, and produced similar hardnesses. In addition, Formula 2 produced a lower vessel to vessel variation in the percent drug released at the 15 minute time point than Formula 1. Again, this is attributable to the use of Starch 1500 in the formulation. The distribution of Starch1500 in the tablets at 20% should be more uniform than 4% CCS. Figure 6. Dissoultion STARCH 1500-8 -

FORMULATION COST ANALYSIS This study has illustrated the multiple properties of Starch 1500 and how it compares to a formulation containing PVP and CCS. As well as bringing performance benefits, Starch 1500 can increase the profitability of a formulation. By replacing the PVP and CCS, both expensive excipients, with Starch 1500, a substantial reduction can be achieved in the raw material cost as well as in the cost of manufacture. Figure 7 is an excipient comparison for Formula 1 containing PVP and CCS. The figure shows the percentage of each excipient that make up the formulation and the associated costs by percentage. While MCC comprises 67% of the excipients, it only represents a small portion of the excipient costs. Together, the PVP and CCS represent nearly 70% of the excipient costs. If the povidone, croscarmellose sodium, and half of the microcrystalline cellulose are replaced with Starch 1500, a cost savings in excess of 60% can be realized. Figure 7. Excipient Comparison Formula 1 CONCLUSIONS This study shows the multifunctional properties of Starch 1500 in a high shear wet granulation application. Starch 1500 performed as an excellent binder producing a granulation that was compressible and produced tablets of improved hardness and friability compared with those prepared with PVP. While providing comparable binding, the Starch 1500 formulation exceeded the disintegration and dissolution performance of the PVP formulation which utilized super disintegrant. The use of Starch 1500 in the formulation showed lower vessel to vessel variation in dissolution than Formula 1 using CCS. In addition, PVP and super disintegrants may have a negative effect on the film coating process and product stability, especially for moisture sensitive drugs. This study has shown that Starch 1500 can produce beneficial results while reducing the overall cost and complexity of a formulation. Starch 1500 can be added directly to the granulator bowl eliminating the need to prepare a binder solution. Also, it was shown that lubricant choices and levels can impact product performance. Ingredients and levels should be justified with data in each formulation. Starch 1500 also has high density and good flow properties and can be used in wet granulation, direct compression, and capsule formulations. In conclusion, using Starch 1500 is an excellent way to reduce process time and cost while preserving optimal properties in a well constructed formulation. STARCH 1500-9 -

Powered by TCPDF (www.tcpdf.org) For more information, contact your Colorcon representative or call: North America Europe/Middle East/Africa Asia Pacific Latin America +1-215-699-7733 +44-(0)-1322-293000 +65-6438-0318 +54-11-4552-1565 You can also visit our website at www.colorcon.com STARCH 1500-10 - Colorcon, 2009. The information contained in this document is proprietary to Colorcon and may not be used or disseminated inappropriately. All trademarks, except where noted, are property of BPSI Holdings, LLC. ads_starch_1500_used_bind_dis_v3_06_2009